Severe aneuploidy, however, may lead to the depletion of HSF1 and could compromise HSP90 chaperone activity [95], suggesting that certain cancer cells may be susceptible to therapies that further disrupt the protein-folding capacity. This evidence concerns the gene HSF1 and cancer.